ArticleJournal of hepatology2021
Cost-effectiveness of alcohol use treatments in patients with alcohol-related cirrhosis.
Article in Journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Economic evaluations of alcohol pharmacotherapy: Systematic review of economic evaluations of pharmacotherapy for the treatment of alcohol use disorder.The Australian and New Zealand journal of psychiatry · 2024Pooled it
- Optimizing outpatient pharmacologic treatment for veterans with alcohol use disorder using an academic detailing approach for primary care providers in the United States Department of Veterans Affairs: A retrospective quasi-experimental study.Addiction (Abingdon, England) · 2026Article
- Emergency Department-initiated Naltrexone for Alcohol Use Disorder: Association with Recidivism.The western journal of emergency medicine · 2026Article
- Quality improvement in hepatology requires a chronic care framework.Hepatology communications · 2026Article
- Balancing abstinence and harm reduction across the continuum of care for liver transplantation in alcohol-associated liver disease.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2025Review
- A cost-effectiveness analysis of two psychological treatments for controlled drinking in individuals alcohol use disorder.Cost effectiveness and resource allocation : C/E · 2025Article
- Alcohol Use Disorder Medication Coverage and Utilization Management in Medicaid Managed Care Plans.JAMA network open · 2025Article
- Alcohol-associated liver disease: Natural history, management and novel targeted therapies.Clinical and molecular hepatology · 2025Review
- Pharmacotherapy for Alcohol Use Disorder Is Underutilized Among Commercially Insured Adults With Alcohol-Associated Liver Disease.Gastro hep advances · 2025Article
- Alcohol-related liver disease.Gastroenterology report · 2025Review
- Monitoring and treatment of alcohol use disorder: an integrated multidisciplinary model.Metabolism and target organ damage · 2025Article
- Missed and Delayed Diagnoses of Chronic Liver Disease in Primary Care Patients with Cirrhosis.Digestive diseases and sciences · 2024Article
- Safety of naltrexone in patients with cirrhosis.JHEP reports : innovation in hepatology · 2024Article
- Pharmacotherapy for alcohol use disorder among adults with medical disorders in Sweden.Addiction science & clinical practice · 2024Article
- Treatment of alcohol use disorder in patients with alcohol-associated liver disease: Innovative approaches and a call to action.Addiction science & clinical practice · 2024Review
- Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2024Article
- The development and evaluation of a provider-focused educational intervention about alcohol use disorder in patients with cirrhosis.Canadian liver journal · 2023Article
- Estimating Joint Health State Utility Algorithms Under Partial Information.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2023Article
- Culture, stigma, and inequities creating barriers in alcohol use disorder management in alcohol-associated liver disease.Clinical liver disease · 2023Article
- Addiction Prescription: A Bridge Between Addiction Medicine and Digestive Diseases.Digestive diseases and sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND &
aimsAlcohol use treatment such as medication-assisted therapies (MATs) and counseling are available and effective in promoting alcohol abstinence. We sought to explore the cost-effectiveness of different alcohol use treatments among patients with compensated alcohol-related cirrhosis (AC).
methodsWe simulated a cohort of patients with compensated AC receiving care from a hepatology clinic over their lifetimes. We estimated costs (in 2017 US$) and benefits in terms of quality-adjusted life years (QALYs) gained from healthcare and societal perspectives. Transition probabilities, costs, and health utility weights were taken from the literature. Treatment effects of FDA-approved MATs (acamprosate and naltrexone) and non-FDA approved MATs (baclofen, gabapentin, and topiramate) and counseling were based on a study of employer-insured patients with AC. We calculated incremental cost-effectiveness ratios (ICERs) and performed one-way and probabilistic sensitivity analyses to understand the impact of parameter uncertainty.
resultsCompared to a do-nothing scenario, MATs and counseling were found to be cost-saving from a healthcare perspective, which means that they provide more benefits with less costs than no intervention. Compared to other interventions, acamprosate and naltrexone cost the least and provide the most QALYs. If the effectiveness of MATs and counseling decreased, these interventions would still be cost-effective based on the commonly used $100,000 per QALY gained threshold. Several sensitivity and scenario analyses showed that our main findings are robust.
conclusionsAmong patients with compensated AC, MATs and counseling are extremely cost-effective, and in some cases cost-saving, interventions to prevent decompensation and improve health. Health policies (e.g. payer reimbursement) should emphasize and appropriately compensate for these interventions. LAY SUMMARY: Alcohol use treatments, including physician counseling and medication-assisted therapies (MATs), improve the outcomes of patients with compensated alcohol-related cirrhosis, though use and access have remained suboptimal. In this study, we found that counseling and MATs are extremely cost-effective, and in some cases cost-saving, interventions to help patients with alcohol-related cirrhosis abstain from alcohol and improve their health. Wider use of these interventions should be encouraged.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.